EMPOWER-Lung 1: A Randomized, Open-Label, Multi-National, Phase III Trial of Cemiplimab, A Human PD-1 Monoclonal Antibody, Versus Chemotherapy In First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With PD-L1 >= 50%
Tarih
2018Yazar
Sriuranpong, V.
Altundag, O.
Clingan, P.
Rizvi, N.
Frontera, O. Aren
Sezer, A.
Paydas, S.
Shavdia, M.
Bondarenko, I.
Gladkov, O.